-Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile,

LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today a

BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or t

Company to Loan $6.5 Million Prior to Closing to Fund Order Backlog and Working Capital Needs – Comb

Announcement Follows the Recent Appointment of Denham Capital Founder Stuart D. Porter — a Three-Dec

LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today a

Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.18) per share. This is a 37.93 pe

Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.34) per share. This is a 25.93 pe

LIXTE Biotechnology Holdings (NASDAQ:LIXT) announced an expansion of its collaboration with The Univ

On December 30, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the "Company&#

--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be present

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the "Company"), a biotech company focused

LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT) a biote

Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.29) per share. This is a 35.56 pe

Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE's Proprietar

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) (the "Company"), a clinical stage pharmaceu

https://ppubs.uspto.gov/api/pdf/downloadPdf/12343342?requestToken=eyJzdWIiOiIxMDU2YWQ0Yy05M2E5LTQyYT